Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isosorbide Dinitrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | BCHE | P06276 | 6/20 | 0.64 |
| ▸ | GSR | P00390 | 8/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosorbide Dinitrate SCHEMBL19528695 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL9439417 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL1553054 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL29532755 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL8253 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL3008938 | 0.98 | ALDH1A1 (0.95) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL714959 | 0.98 | ALDH1A1 (0.95) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL27976716 | 0.96 | ALDH1A1 (0.91) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL28209664 | 0.96 | ALDH1A1 (0.91) | ALDH1A1MAPTBCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL3864281 | 0.94 | ALDH1A1 (0.88) | ALDH1A1MAPTBCHEGSRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1958 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-20230174641-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | H LUNDBECK AS (DK) | 2023-06-08 | — | — | US | claimed |
| US-20220184039-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES RELATING THERETO | ANKURA TRUST COMPANY, LLC | 2022-06-16 | — | — | US | claimed |
| CN-113207754-A | Bathing device for breeding golden sparrow | 冉瑞华 | 2021-08-06 | — | — | CN | claimed |
| EP-3835319-A1 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | Alder Biopharmaceuticals, Inc. (US) | 2021-06-16 | — | — | EP | claimed |
| CN-107506739-B | Night forward vehicle detection and distance measurement method | 南京富士通南大软件技术有限公司 | 2021-01-12 | — | — | CN | claimed |
| EP-3753950-A2 | ANTI-PCSK9 ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2020-12-23 | — | — | EP | claimed |
| US-20200317772-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | ALDERBIO HOLDINGS LLC (US) | 2020-10-08 | — | — | US | claimed |
| US-20200222369-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES RELATING THERETO | ANKURA TRUST COMPANY, LLC | 2020-07-16 | — | — | US | claimed |
| US-10639297-B2 | Ophthalmic pharmaceutical compositions and uses relating thereto | ORASIS PHARMACEUTICALS LTD. (IL) | 2020-05-05 | — | — | US | claimed |
| CN-1616047-A | Anti-inflammatory and keeping adverse energy downwards capsule for treating asthma, pulmonary emphysema and SARS | LIANG HAIDONG (CN) | 2005-05-18 | — | — | CN | claimed |
| EP-1521411-A2 | Method and apparatus for request/grant priority scheduling | ALCATEL (FR) | 2005-04-06 | — | — | EP | claimed |
| CN-1571662-A | Highly compressible ethylcellulose for tableting | HERCULES INC (US) | 2005-01-26 | — | — | CN | claimed |
| CN-1418091-A | Pharmaceutical preparations | AWD PHARMA GMBH & CO KG (DE) | 2003-05-14 | — | — | CN | claimed |
| CN-1375331-A | Antiphlogistic capsule capable of keeping the adverse energy downwards | LIANG HAIDONG (CN) | 2002-10-23 | — | — | CN | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| CN-1109742-A | Toothpaste for health of cardio-cerebral blood vessel | XU WOXIAN (CN) | 1995-10-11 | — | — | CN | claimed |
| CN-2112399-U | HEART ACHE ACUPOINT THERAPEUTIC DEVICE | XIANG DONG (CN) | 1992-08-12 | — | — | CN | claimed |
| US-4631273-A | TRANSFER TO SUBSTRATE WITHOUT RE-WETTING OR RE-SOLUBILIZING | DOW CORNING CORPORATION (US) | 1986-12-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174641-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | CRH, MC2R, GIPR | ALDH1A1 4182/4885MAPT 604/4885BCHE 763/4885 |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | ALDH1A1 2724/4885MAPT 3953/4885BCHE 301/4885 |
| US-20200317772-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | CRH, MC2R, GIPR | ALDH1A1 4182/4885MAPT 604/4885BCHE 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.